World-first gene therapy to target devastating rare immune disorder
29 Jun 2026, 11:16 a.m.
A first-of-its-kind gene therapy to treat people with CTLA-4 insufficiency is being advanced through a collaboration supported by LifeArc, and developed by scientists at UCL, with manufacturing support from NHS Blood and Transplant and GOSH.
Read more